{
    "clinical_study": {
        "@rank": "94231", 
        "arm_group": [
            {
                "arm_group_label": "Chardonnay Seed Flour (CSF)", 
                "arm_group_type": "Active Comparator", 
                "description": "Prepackaged capsules taken 3 times per day.  During the first month, the total dose will be 15 g/d.  For months 2-4, the total dose will be 30 g/d."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Pre-packaged capsules taken 3 times per day.  For the first month, a total of 15 g/d.   During months 2 - 4, a total of 30 g/d."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blinded trial (Chardonnay seed flour vs. placebo - in pill\n      form) with the purpose to test the impact of a four-month supplementation with Chardonnay\n      Seed Flour (CSF) on endothelial function.  Chardonnay flour is made from wine grape skins\n      and seeds.  We will examine the effect of CSF on parameters such as endothelial function\n      (via EndoPAT testing), plasma lipid levels, glucose tolerance, insulin resistance,\n      inflammatory markers, oxidative stress surrogates, endothelial progenitor cells (EPCs) as\n      well as  the makeup of and impact on the gut microbiome (via stool samples)."
        }, 
        "brief_title": "Effects of Chardonnay Seed Flour on Vascular Health", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "1. Endothelial Dysfunction (EndoPAT Score <=2)", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age >= 18 years old\n\n          2. Demonstrated endothelial dysfunction (EndoPAT score <= 2) at time of  screening.\n\n        Exclusion criteria:\n\n          1. Age below 18 or above 80\n\n          2. Endothelial function greater than 2.0 at baseline\n\n          3. Hypertension (at screening):  any patient with systolic blood pressure (SBP >=170\n             mmHg or diastolic blood pressure >= 110 mmHg, or hypotension (SBP < 100 mmHg\n\n          4. Abnormal liver function tests\n\n          5. Uncontrolled Diabetes Mellitus or the use of metformin for Diabetes Mellitus\n\n          6. Difficulty swallowing capsules\n\n          7. Gastrointestinal disease manifesting with symptoms of malabsorption such as celiac\n             disease or Crohn's disease\n\n          8. Non-English speakers\n\n          9. Vulnerable populations unable to consent such as prisoners or dependents\n\n         10. Any surgical or medical condition which might significantly alter the absorption,\n             distribution, metabolism, or excretion of the CSF including, but not limited to, any\n             of the following:\n\n               1. History of major gastrointestinal tract surgery such as gastrectomy,\n                  gastroenterostomy or bowel resection\n\n               2. Any history of pancreatic injury, pancreatitis or evidence of impaired\n                  pancreatic function/injury as indicated by abnormal lipase or amylase\n\n               3. Evidence of hepatic disease as determined by a history of hepatic\n                  encephalopathy, a history of cirrhosis, esophageal varices, or a history of\n                  portocaval shunt.\n\n         11. History of hypersensitivity to any of the study supplement or suspected\n             contraindications to the study supplement.\n\n         12. History of noncompliance to medical regimens or unwillingness to comply with the\n             study protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093455", 
            "org_study_id": "13-007023"
        }, 
        "intervention": [
            {
                "arm_group_label": "Chardonnay Seed Flour (CSF)", 
                "description": "CSF is made from wine grape skins and seeds.", 
                "intervention_name": "Chardonnay Seed Flour (CSF)", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Endothelial function", 
        "lastchanged_date": "May 9, 2014", 
        "location": {
            "contact": {
                "email": "nelson.rebecca@mayo.edu", 
                "last_name": "Rebecca E. Nelson, CCRC", 
                "phone": "507-255-8388"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }, 
            "investigator": {
                "last_name": "Lerman Amir, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Chardonnay Seed Flour on Vascular Health", 
        "overall_contact": {
            "email": "nelson.rebecca@mayo.edu", 
            "last_name": "Rebecca E. Nelson, CCRC", 
            "phone": "507-255-8388"
        }, 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Amir Lerman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Endothelial function (Endothelial Peripheral Arterial Tonometry - EndoPAT) Testing will generate a score at baseline that will be compared to a second EndoPAT test which will be conducted again after the study subjects have taken the study product for 4 months.  These scores will be used to determine if the study product had an effect on endothelial function.", 
            "measure": "Endothelial function as measured by reactive hyperemia EndoPAT scores", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093455"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Amir Lerman", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Change in High Sensitive C-reactive protein (hsCRP)", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 4 months"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "collaborator": {
                "agency": "Whole Vine Products", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}